investor harm

Class action lawsuit filed against CoreWeave for allegedly making false statements about operational capabilities and customer demand fulfillment. Investors who purchased stock during specified period may seek lead plaintiff status.

Beyond Meat faces class action lawsuit alleging leadership concealed material asset impairment charges, misleading investors during nine-month period ending November 2025.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

uniQure faces class action lawsuit alleging misleading FDA approval statements and understated BLA timeline risks. Investors who purchased securities between September-October 2025 may be eligible to participate.

BlackRock TCP Capital faces class action lawsuit alleging false valuations and misleading net asset value disclosures. Shareholders who bought shares between November 2024 and January 2026 may participate.

Paysafe Limited faces class action lawsuit alleging undisclosed risks including high-risk client concentration and understated credit reserves, misleading investors about financial stability.

CIBC and RBC face class action lawsuit for allegedly using spoofed orders to manipulate Quantum Biopharma stock price downward, harming investors from 2021-2025.

Class action lawsuit filed against Picard Medical for alleged fraud involving false social media statements and insider stock sales during inflated prices.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.

Ultragenyx faces class action lawsuit for allegedly misleading investors about setrusumab efficacy and failing to disclose Phase III trial risks adequately.

Ramaco Resources faces class action lawsuit for allegedly misrepresenting Brook Mine's operational status, failing to disclose lack of mining activity despite groundbreaking ceremony claims.

Class action lawsuit filed against agilon health for allegedly making false 2026 guidance claims and overstating benefits of risk reduction initiatives, affecting investors from February-August 2025.

Mereo BioPharma faces class action lawsuit over allegedly misleading disclosures about failed Phase 3 clinical trials. Investors who purchased shares between June 2023 and December 2025 may be eligible.

Class action lawsuit filed against Smart Digital Group for allegedly failing to disclose market manipulation and fraudulent promotional activities that harmed investors between May and September 2025.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

Klarna faces class action lawsuit alleging it misrepresented loan portfolio risks and understated credit exposure in its September 2025 IPO.

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities artificially inflated stock prices, harming shareholders during February-October 2025.

Class action lawsuit filed against Sallie Mae for allegedly concealing loan delinquency increases and overstating loss mitigation effectiveness, artificially inflating stock prices during July-August 2025.

Ultragenyx Pharmaceutical faces class action lawsuit for allegedly making false statements about setrusumab drug efficacy and safety, affecting investors who bought securities between August 2023 and December 2025.

Bath & Body Works faces a class action lawsuit for allegedly making false statements about its growth strategy's effectiveness and failing to disclose poor results to investors.